Age-Related Gender Differences in Expression Levels of Tau Interacting-Ubiquitin Specific Peptidase-9
Principal Investigator
Enrico Glaab, PhD
University of Luxembourg
Esch-Belval Esch-sur-Alzette, Luxembourg
About the Research Project
Program
Award Type
Bold Ideas initiatives
Award Amount
$50,000
Active Dates
January 01, 2014 - December 31, 2014
Grant ID
C2014002
Acknowledgement
Goals
This study examines whether a specific gene on the Y chromosome can confer protection against Alzheimer’s disease. If so, this protection may explain some of the gender differences that make females more susceptible to Alzheimer’s than males.
Summary
Recent studies on aging of the human brain show that age-related gene expression changes may display significant differences between the genders. One of the genes with the largest differences between male and female expression levels across multiple brain regions during adulthood is the Y chromosomal ubiquitin-specific peptidase 9 (USP9Y; the differences are not compensated by the female homologue USP9X). Interestingly, in post-mortem brain samples from male Alzheimer’s disease (AD) patients a significant down-regulation of USP9Y is observed as compared to unaffected male controls, while no significant changes are detected for USP9X. Studying the protein interaction network reveals associations of USP9Y with microtubule-associated protein tau (MAPT), known for the formation of neurofibrillary tangles in AD, and with SIRT1, previously linked with aging/longevity and AD. USP9X/Y is also a known regulator of the TGF-beta/BMP signaling pathway and deubiquitinates monoubiquitinated SMAD4, opposing the inhibitory activity of E3 ubiquitin-protein ligase TRIM33 and resulting in downstream TGF-beta activation. Since previous studies showed neuroprotective effects for TGF-beta activation in multiple in-vitro and in-vivo models of neurodegeneration, and fly AD models affirm an involvement of USP9X/Y in MAPT regulation, the combined observations suggest that age-dependent higher USP9X/Y levels in males may contribute to previously observed gender differences in AD.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD